CTTQ
Status and phase
Conditions
Treatments
About
This is a phase Ib/II exploratory study. Phase Ib includes the dose escalation and expansion study of monotherapy, as well as the dose escalation study of combination therapy. After determining the maximum tolerated dose (MTD), a dose expansion study is conducted to observe the safety and efficacy in monotherapy. Phase II study is to further observe the safety and efficacy of TQB2930 combined with albumin-paclitaxel (cohort 3), or chemotherapy selected by investigators (cohort 4).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0~1; The expected survival is over 3 months.
Phase Ib
Phase II
Major organs are functioning normally.
Female subjects of reproductive age should agree to use contraceptive methods during the study period and until 6 months after the end of the study; Negative serum pregnancy / urine pregnancy test within 7 days prior to study enrollment and must be non-lactating subjects; Male subjects should agree to use contraception during the study and until six months after the end of the study.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
154 participants in 4 patient groups
Loading...
Central trial contact
Qingyuan Zhang, Doctor; Xiaohua Zeng, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal